CHICAGO, July 13, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into an agreement for the commercialization of its type-2 diabetes medication DIABIT-IS X (sitagliptin phosphate) in the Greek market, through a distribution and promotion partnership with Libytec Pharmaceutical S.A. ("Libytec").
Read more at globenewswire.comCosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
Barchart·07/13/2026 12:00:00
语音播报
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.